Innoviva Stock Performance
| INVA Stock | USD 18.03 0.05 0.28% |
The company retains a Market Volatility (i.e., Beta) of 0.34, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Innoviva's returns are expected to increase less than the market. However, during the bear market, the loss of holding Innoviva is expected to be smaller as well. At this point, Innoviva has a negative expected return of -0.0855%. Please make sure to check out Innoviva's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Innoviva performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Innoviva has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Innoviva is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (0.28) | Five Day Return (0.83) | Year To Date Return 3.62 | Ten Year Return 4.21 | All Time Return 32.94 |
Last Split Factor 1241:1000 | Dividend Date 2015-09-30 | Ex Dividend Date 2015-09-08 | Last Split Date 2014-06-03 |
1 | Systematic Financial Management LP Grows Stock Position in Innoviva, Inc. | 12/05/2024 |
2 | Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera in the United States | 12/16/2024 |
3 | Innoviva, Inc.s Popularity With Investors Is Under Threat From Overpricing | 12/19/2024 |
4 | Innoviva investors are up 4.7 percent in the past week, but earnings have declined over the last five years | 01/16/2025 |
5 | Innoviva, Inc. Shares Purchased by China Universal Asset Management Co. Ltd. | 02/03/2025 |
6 | Innoviva Shares Cross Below 200 DMA - Nasdaq | 02/11/2025 |
7 | Disposition of 1106 shares by Basso Stephen of Innoviva at 18.07 subject to Rule 16b-3 | 02/20/2025 |
| Begin Period Cash Flow | 291 M |
Innoviva |
Innoviva Relative Risk vs. Return Landscape
If you would invest 1,899 in Innoviva on November 28, 2024 and sell it today you would lose (96.00) from holding Innoviva or give up 5.06% of portfolio value over 90 days. Innoviva is currently does not generate positive expected returns and assumes 0.8909% risk (volatility on return distribution) over the 90 days horizon. In different words, 7% of stocks are less volatile than Innoviva, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innoviva Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innoviva's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Innoviva, and traders can use it to determine the average amount a Innoviva's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.096
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INVA |
Estimated Market Risk
| 0.89 actual daily | 7 93% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Innoviva is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innoviva by adding Innoviva to a well-diversified portfolio.
Innoviva Fundamentals Growth
Innoviva Stock prices reflect investors' perceptions of the future prospects and financial health of Innoviva, and Innoviva fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innoviva Stock performance.
| Return On Equity | 0.0997 | ||||
| Return On Asset | 0.0937 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.48 % | ||||
| Current Valuation | 1.32 B | ||||
| Shares Outstanding | 62.6 M | ||||
| Price To Earning | 5.67 X | ||||
| Price To Book | 1.69 X | ||||
| Price To Sales | 3.20 X | ||||
| Revenue | 310.46 M | ||||
| Gross Profit | 297.14 M | ||||
| EBITDA | 248.96 M | ||||
| Net Income | 179.72 M | ||||
| Cash And Equivalents | 283.58 M | ||||
| Cash Per Share | 4.07 X | ||||
| Total Debt | 449.08 M | ||||
| Debt To Equity | 0.96 % | ||||
| Current Ratio | 3.18 X | ||||
| Book Value Per Share | 10.68 X | ||||
| Cash Flow From Operations | 141.06 M | ||||
| Earnings Per Share | 0.80 X | ||||
| Market Capitalization | 1.13 B | ||||
| Total Asset | 1.24 B | ||||
| Retained Earnings | (25.19 M) | ||||
| Working Capital | 306.08 M | ||||
| Current Asset | 214.32 M | ||||
| Current Liabilities | 13.49 M | ||||
About Innoviva Performance
By analyzing Innoviva's fundamental ratios, stakeholders can gain valuable insights into Innoviva's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Innoviva has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innoviva has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 346.15 | 363.46 | |
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.13 | 0.14 | |
| Return On Equity | 0.24 | 0.26 |
Things to note about Innoviva performance evaluation
Checking the ongoing alerts about Innoviva for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Innoviva help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innoviva generated a negative expected return over the last 90 days | |
| Innoviva is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Innoviva Shares Cross Below 200 DMA - Nasdaq |
- Analyzing Innoviva's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innoviva's stock is overvalued or undervalued compared to its peers.
- Examining Innoviva's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innoviva's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innoviva's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innoviva's stock. These opinions can provide insight into Innoviva's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Innoviva Stock analysis
When running Innoviva's price analysis, check to measure Innoviva's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innoviva is operating at the current time. Most of Innoviva's value examination focuses on studying past and present price action to predict the probability of Innoviva's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innoviva's price. Additionally, you may evaluate how the addition of Innoviva to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |